Interestingly, though there was a slightly increased incidence of vasculitis and NMJ disorder complications in melanoma patients receiving both PD-1 and CTLA-4 inhibitor therapies, this difference was not statistically significant. The gene discussed is CTLA4; the disease is melanoma.